Isolated testicular relapse (ITR) of ALL after allo-SCT is an uncommon event and a significant management dilemma. Case reports of therapy for ITR post-SCT are few, and therapeutic options range from palliation to second transplantation (see online Supplementary Table 1) . Here we report the largest series to date of seven boys with ITR post-SCT, treated at a single institution with systemic chemotherapy and without a second SCT. Five of the seven boys remain in remission. BM samples for two boys were available during the entire course of their disease for comparison of minimal residual disease (MRD) before and after SCT.
A retrospective review of the management and outcomes of boys with ITR post-SCT identified from the Sydney Children's Hospital (SCH) database from 1979 to 2008 was undertaken. MRD analysis was performed on BM using real-time quantitative PCR detection of patient-specific rearrangements of Ig heavy and kappa chain genes and T-cell receptor delta and gamma genes according to established methods.
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A total of 96 allo-SCTs for boys with ALL were performed, and seven (7.3%) cases of ITR post-SCT were identified. The characteristics of these patients are detailed in Table 1 . The median age at initial diagnosis was 3.2 years (range 2.1-8.6 years), and no patient had initial testicular involvement. All boys received standard therapy according to the era-specific national ALL study, except patient 4 who initially presented with a B-cell non-Hodgkin's lymphoma and subsequently had a BM relapse with ALL.
At first relapse, all the patients received systemic reinduction chemotherapy and those boys who had testicular involvement received local therapy with unilateral orchidectomy (patient 3) or radiation (patients 6 and 7). None of the patients received testicular biopsies or prophylactic testicular radiation boosts as part of conditioning for SCT, and no patients experienced chronic GVHD.
The median time to ITR post-SCT was 12 months (range 4-27 months), and all patients were offered therapy with curative intent. Patient 1 received reinduction with prednisolone, vindesine, daunorubicin, L-asparaginase and intrathecal MTX, followed by 18 months of cyclical maintenance consisting of prednisolone, vincristine, daunorubicin, mercaptopurine, cytarabine and oral and intrathecal MTX. Patient 2 received reinduction with prednisolone, teniposide, cytarabine and L-asparaginase followed by 2 years of cyclical maintenance with prednisolone, vindesine, thioguanine, and oral and intrathecal MTX. Patient 3 received reinduction with idarubicin, MTX and L-asparaginase followed by an unspecified maintenance programme. Patient 4 received reinduction with dexamethasone, vincristine, daunorubicin, L-asparaginase, teniposide, cytarabine and triple intrathecal therapy (MTX, cytarabine and hydrocortisone), followed by 2 years cyclical maintenance with dexamethasone, vindesine, thioguanine, MTX, cytarabine, L-asparaginase, oral etoposide, CY and triple intrathecal therapy. Patient 6 did not receive reinduction therapy and had 2 years of cyclical maintenance with dexamethasone, vincristine, mercaptopurine, oral and intrathecal MTX, thioguanine, CY, teniposide and cytarabine. Patients 5 and 7 received treatment according to arm 1 of protocol POG 8304, 2 which consisted of reinduction with prednisolone, vincristine and doxorubicin, followed by continuation therapy with cyclical mercaptopurine, MTX, prednisolone, vincristine, doxorubicin, CY, and a late intensification phase using prednisolone, vincristine and doxorubicin. On this protocol, the central nervous system chemoprophylaxis was with triple intrathecal therapy and treatment was for a total of 88 weeks.
Local therapy post-SCT was determined by any previous local therapy-orchidectomy was performed in those boys previously irradiated and radiation therapy administered to the remainder. None of the patients received a second SCT. The median survival post-ITR was 61 months (range 23-209 months), and a time to ITR of greater than 12 months from SCT was associated with a favourable prognosis. Five (71%) of the boys are currently alive, four are long-term survivors and one is in remission at the completion of therapy. Two of the boys have died, both of whom had ITR less than 12 months after SCT-patients 1 and 3 suffered a BM relapse 28 and 11 months, respectively after ITR and died of progressive disease. MRD data were available for the most recent two boys (patients 6 and 7) and is shown in Figure 1 . Both boys had MRD detectable in the BM at the time of marrow relapse, but not at the time of clinical ITR.
Attempted strategies to prevent testicular relapse post-SCT have included identification of residual leukaemia through bilateral testicular biopsies before transplant 3 or the inclusion of a testicular radiation boost during conditioning. 4 Pre-symptomatic testicular biopsy was previously widely performed but has not been shown to improve long-term survival. 5 Diagnostic accuracy of biopsies can be improved by MRD testing of testicular tissue 6 but is of limited value in the absence of routine testicular sampling. The addition of a testicular radiation boost to conventional TBI-based conditioning, while reducing the risk of testicular relapse, is accompanied by significant endocrine sequelae and would be an untargeted therapy affecting all boys.
Local therapy alone is insufficient for long-term survival as without systemic therapy BM relapse will almost inevitably follow ITR. Management strategies which have resulted in long-term survival of patients with ITR post-SCT have included orchidectomy or radiation with oral chemotherapy, 7 local therapy with intensive systemic chemotherapy (as in this report) and second SCT. 8 The reported chemotherapy regimens are heterogeneous, and our institution has recently used the POG 8304 protocol 2 with good results and minimal toxicity.
The testes have long been considered a 'sanctuary site' for leukaemia, with the blood-testis interface providing a barrier to chemotherapy, and TBI not always effective in preventing testicular relapse post-SCT. ITR is conventionally defined as testicular involvement with o5% leukaemic blasts in the BM on light microscopic assessment. The advent of MRD techniques now permits detection of sub-microscopic BM involvement in cases of apparent ITR, and while MRD appears to be a prognostic factor in apparent isolated central nervous system relapses, its value in testicular relapse remains to be determined. 9 In the two boys reported here for whom MRD data was available, both were MRD negative in the BM at time of ITR post-SCT, supporting the concept of the testes as a sanctuary site and suggesting that marrow MRD should be further studied as a prognostic factor in this patient population. of therapy for patients 6 (a) and 7 (b). Both patients had a combined relapse involving BM and testes (black arrow) and had MRD detectable in the marrow collected before SCT (white arrow). Both patients had an isolated testicular relapse post transplant with no detectable residual disease in the marrow (striped arrow). Following treatment they remain in CR3 and MRD negative.
VA

